CTN-0051: Extended-Release Naltrexone vs. Buprenorphine for Opioid Treatment
Phase of Trial: Phase IV
Latest Information Update: 31 May 2019
Price : $35 *
At a glance
- Drugs Buprenorphine/naloxone (Primary) ; Naltrexone (Primary)
- Indications Opioid abuse
- Focus Therapeutic Use
- 14 Feb 2018 According to an Alkermes media release, results were published in in The Lancet.
- 21 Mar 2017 Status changed from active, no longer recruiting to completed.
- 13 Dec 2016 Planned primary completion date changed from 1 Nov 2016 to 1 Feb 2017.